• Something wrong with this record ?

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial

M. Lindhardt, F. Persson, G. Currie, C. Pontillo, J. Beige, C. Delles, H. von der Leyen, H. Mischak, G. Navis, M. Noutsou, A. Ortiz, PL. Ruggenenti, I. Rychlik, G. Spasovski, P. Rossing,

. 2016 ; 6 (3) : e010310. [pub] 20160302

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Observational Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000381

INTRODUCTION: Diabetes mellitus affects 9% of the European population and accounts for 15% of healthcare expenditure, in particular, due to excess costs related to complications. Clinical trials aiming for earlier prevention of diabetic nephropathy by renin angiotensin system blocking treatment in normoalbumuric patients have given mixed results. This might reflect that the large fraction of normoalbuminuric patients are not at risk of progression, thereby reducing power in previous studies. A specific risk classifier based on urinary proteomics (chronic kidney disease (CKD)273) has been shown to identify normoalbuminuric diabetic patients who later progressed to overt kidney disease, and may hold the potential for selection of high-risk patients for early intervention. Combining the ability of CKD273 to identify patients at highest risk of progression with prescription of preventive aldosterone blockade only to this high-risk population will increase power. We aim to confirm performance of CKD273 in a prospective multicentre clinical trial and test the ability of spironolactone to delay progression of early diabetic nephropathy. METHODS AND ANALYSIS: Investigator-initiated, prospective multicentre clinical trial, with randomised double-masked placebo-controlled intervention and a prospective observational study. We aim to include 3280 type 2 diabetic participants with normoalbuminuria. The CKD273 classifier will be assessed in all participants. Participants with high-risk pattern are randomised to treatment with spironolactone 25 mg once daily, or placebo, whereas, those with low-risk pattern will be observed without intervention other than standard of care. Treatment or observational period is 3 years.The primary endpoint is development of confirmed microalbuminuria in 2 of 3 first morning voids urine samples. ETHICS AND DISSEMINATION: The study will be conducted under International Conference on Harmonisation - Good clinical practice (ICH-GCP) requirements, ethical principles of Declaration of Helsinki and national laws. This first new biomarker-directed intervention trial aiming at primary prevention of diabetic nephropathy may pave the way for personalised medicine approaches in treatment of diabetes complications. TRIAL REGISTRATION NUMBER: NCT02040441; Pre-results.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000381
003      
CZ-PrNML
005      
20170113095746.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2015-010310 $2 doi
024    7_
$a 10.1136/bmjopen-2015-010310 $2 doi
035    __
$a (PubMed)26936907
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lindhardt, Morten $u Steno Diabetes Center, Gentofte, Denmark.
245    10
$a Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial / $c M. Lindhardt, F. Persson, G. Currie, C. Pontillo, J. Beige, C. Delles, H. von der Leyen, H. Mischak, G. Navis, M. Noutsou, A. Ortiz, PL. Ruggenenti, I. Rychlik, G. Spasovski, P. Rossing,
520    9_
$a INTRODUCTION: Diabetes mellitus affects 9% of the European population and accounts for 15% of healthcare expenditure, in particular, due to excess costs related to complications. Clinical trials aiming for earlier prevention of diabetic nephropathy by renin angiotensin system blocking treatment in normoalbumuric patients have given mixed results. This might reflect that the large fraction of normoalbuminuric patients are not at risk of progression, thereby reducing power in previous studies. A specific risk classifier based on urinary proteomics (chronic kidney disease (CKD)273) has been shown to identify normoalbuminuric diabetic patients who later progressed to overt kidney disease, and may hold the potential for selection of high-risk patients for early intervention. Combining the ability of CKD273 to identify patients at highest risk of progression with prescription of preventive aldosterone blockade only to this high-risk population will increase power. We aim to confirm performance of CKD273 in a prospective multicentre clinical trial and test the ability of spironolactone to delay progression of early diabetic nephropathy. METHODS AND ANALYSIS: Investigator-initiated, prospective multicentre clinical trial, with randomised double-masked placebo-controlled intervention and a prospective observational study. We aim to include 3280 type 2 diabetic participants with normoalbuminuria. The CKD273 classifier will be assessed in all participants. Participants with high-risk pattern are randomised to treatment with spironolactone 25 mg once daily, or placebo, whereas, those with low-risk pattern will be observed without intervention other than standard of care. Treatment or observational period is 3 years.The primary endpoint is development of confirmed microalbuminuria in 2 of 3 first morning voids urine samples. ETHICS AND DISSEMINATION: The study will be conducted under International Conference on Harmonisation - Good clinical practice (ICH-GCP) requirements, ethical principles of Declaration of Helsinki and national laws. This first new biomarker-directed intervention trial aiming at primary prevention of diabetic nephropathy may pave the way for personalised medicine approaches in treatment of diabetes complications. TRIAL REGISTRATION NUMBER: NCT02040441; Pre-results.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a biologické markery $7 D015415
650    _2
$a diabetes mellitus 2. typu $x komplikace $7 D003924
650    _2
$a diabetické nefropatie $x prevence a kontrola $7 D003928
650    _2
$a progrese nemoci $7 D018450
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a proteomika $x metody $7 D040901
650    12
$a renin-angiotensin systém $7 D012084
650    12
$a výzkumný projekt $7 D012107
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Persson, Frederik $u Steno Diabetes Center, Gentofte, Denmark.
700    1_
$a Currie, Gemma $u Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
700    1_
$a Pontillo, Claudia $u Mosaiques Diagnostics, Hannover, Germany.
700    1_
$a Beige, Joachim $u Klinikum St. Georg, Nephrology and KfH Renal Unit, Leipzig, Germany Martin-Luther-University Halle, Wittenberg, Germany.
700    1_
$a Delles, Christian $u Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
700    1_
$a von der Leyen, Heiko $u Hannover Clinical Trial Center, Hannover, Germany.
700    1_
$a Mischak, Harald $u Mosaiques Diagnostics, Hannover, Germany.
700    1_
$a Navis, Gerjan $u Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.
700    1_
$a Noutsou, Marina $u Diabetes Center, Geniko Nosokomeio Athinas Ippokrateio, Athens, Greece.
700    1_
$a Ortiz, Alberto $u Instituto de Investigacion Sanitaria de la Fundacion Jimenez D¡az (IIS-FJD UAM), Madrid, Spain.
700    1_
$a Ruggenenti, Piero Luigi $u Istituto di Richerche Farmacologiche Mario Negri, Bergamo, Italy.
700    1_
$a Rychlik, Ivan $u 2nd Department of Medicine, 3rd Faculty of Medicine, Universita Karlova v Praze, Prague, Czech Republic.
700    1_
$a Spasovski, Goce $u Department of Nephrology, Cyril and Methodius University in Skopje, Skopje, Former Yugoslav Republic of Macedonia.
700    1_
$a Rossing, Peter $u Steno Diabetes Center, Gentofte, Denmark The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 6, č. 3 (2016), s. e010310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26936907 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170113095847 $b ABA008
999    __
$a ok $b bmc $g 1179521 $s 960948
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 6 $c 3 $d e010310 $e 20160302 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options